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Abstract
Conventional drugs treat diabetes by improving insulin sensitivity, increasing insulin production
and/or decreasing the amount of glucose in blood. Several herbal preparations are used to treat
diabetes, but their reported hypoglycemic effects are complex or even paradoxical in some cases.
This article reviews recent findings about some of the most popular hypoglycemic herbs, such as
ginseng, bitter melon and Coptis chinensis. Several popular commercially available herbal
preparations are also discussed, including ADHF (anti-diabetes herbal formulation), Jiangtangkeli,
YGD (Yerbe Mate-Guarana-Damiana) and BN (Byakko-ka-ninjin-to). The efficacy of hypoglycemic
herbs is achieved by increasing insulin secretion, enhancing glucose uptake by adipose and muscle
tissues, inhibiting glucose absorption from intestine and inhibiting glucose production from
heptocytes.
Background
Diabetes mellitus is a disease in which blood glucose lev-
els are above normal [1]. There are three main types of
diabetes, namely type I diabetes (juvenile diabetes), type
II diabetes and gestational diabetes. In type I diabetes, the
β cells of the pancreas do not make sufficient insulin. Type
II diabetes is the major form of diabetes, accounting for
approximately 90–95% of all diabetic cases. This form of
diabetes usually begins with insulin insensitivity, a condi-
tion in which muscle, liver and fat cells do not respond to
insulin properly. The pancreas eventually loses the ability
to produce and secrete enough insulin in response to food
intake. Gestational diabetes is caused by hormonal
changes during pregnancy or by insulin insufficiency.
Glucose in the blood fails to enter cells, thereby increasing
the glucose level in the blood. High blood glucose, also
known as hyperglycemia, can damage nerves and blood
vessels, leading to complications such as heart disease,
stroke, kidney dysfunction, blindness, nerve problems,
gum infections and amputation [2]. Insulin injections,
glucose-lowering drugs and lifestyle changes, such as exer-
cise, weight control and diet therapy, are recommended
for treating diabetes.
Hypoglycemic herbs are widely used as non-prescription
treatment for diabetes [3]. However, few herbal medicines
have been well characterized and demonstrated the effi-
cacy in systematic clinical trials as those of Western drugs.
This review article highlights the current researches on the
efficacy, side effects and action mechanisms of hypoglyc-
emic herbs in vitro, in vivo and ex-vivo systems [4].
Conventional diabetic drugs
Western diabetic drugs correct hypoglycemia by supple-
menting insulin, improving insulin sensitivity, increasing
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insulin secretion from the pancreas and/or glucose uptake
by tissue cells. Under normal conditions, pancreatic β-
cells secrete sufficient insulin to maintain blood glucose
concentration within a narrow range (72–126 mg/dL) [5]
(Figure 1). The insulin stimulation followed by cascade
signaling enhances glucose intake, utilization and storage
in various tissues (Figure 2). In diabetic patients, the body
loses insulin producing capacity as a result of pancreatic β-
cell apoptosis or insulin insensitivity. The cytokines, lipo-
toxicity and gluco-toxicity are three major stimuli for β-
cell apoptosis [6] (Figure 1).
There are several types of glucose-lowering drugs [7] (Fig-
ure 3), including insulin secretagogues (sulfonylureas,
meglitinides), insulin sensitizers (biguanides, metformin,
thiazolidinediones),  α-glucosidase inhibitors (miglitol,
acarbose). New peptide analogs, such as exenatide,
liraglutide and DPP-4 inhibitors, increase GLP-1 serum
concentration and slow down the gastric emptying [8,9].
Most glucose-lowering drugs, however, may have side
effects, such as severe hypoglycemia, lactic acidosis, idio-
syncratic liver cell injury, permanent neurological deficit,
digestive discomfort, headache, dizziness and even death
[10].
Anti-diabetes herbs
Certain herbs may lower blood glucose [3,11]; however,
their test results are subject to several factors. Firstly, each
herb contains thousands of components, only a few of
which may be therapeutically effective [12]. Secondly, dif-
ferent parts of an herb have different ingredient profiles.
Moreover, different extraction methods may yield differ-
ent active ingredients [13]. Thirdly, herbal formulae con-
taining multiple herbs may have synergistic effects
[14,15].
Ginseng
The therapeutic potency of ginseng mainly relies on its
geographical locality, dosage, processing and types of dia-
betes. Panax ginseng (Chinese or Korean ginseng) has the
Insulin secretion and pancreatic-β-cell apoptosis Figure 1
Insulin secretion and pancreatic-β-cell apoptosis. Glucose is taken up into β-cells via glucose transporters. It is metabo-
lized in glycolysis and Krebs cycle, resulting in an increased ratio of ATP to ADP in the cytoplasm. This closes ATP-sensitive 
potassium channels (KATP channels), leading to cell membrane depolarization and subsequently opening voltage-gated Ca2+ 
channels. These changes increase free Ca2+ concentration ([Ca2+]i) in cytoplasm and eventually triggers insulin secretion. In 
apoptosis, stimuli promotes the release of caspase activators from mitochondria and result in the activation of caspases proce-
dure, by cleaving the effector caspases, which interacts with a variety of cellular proteins, resulting in directly or indirectly the 
morphological and biochemical characteristics of cell apoptosis. The action sites of hypoglycemia herbs are indicated with a 
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highest therapeutic potency. Panax quinquefolius (Ameri-
can ginseng) is the medium potency grade ginseng, while
Panax japonicus (Japanese ginseng) is considered the low
potency grade ginseng. Thus, the most commonly used
therapeutic ginseng is Panax ginseng. The anti-tumor, angi-
omodulating and steroid-like activities of ginseng have
been recently delineated [16].
The anti-diabetic effects of ginseng have been investigated
with aqueous or ethanol ginseng extracts. A proposed
action mechanism has been tested on various animal
models [17]. Korean red ginseng (0.1–1.0 g/ml) signifi-
cantly stimulated insulin release from isolated rat pancre-
atic islets at 3.3 mM glucose concentration [18]. The
treatment with oral administration of H-AG (heat-proc-
essed American ginseng) at a dose of 100 mg/kg of body
weight for 20 days decreased serum levels of glucose and
glycosylated proteins and hemoglobin A1C in streptozo-
tocin (STZ)-induced diabetic rats. The treatment also
improved the decreased creatinine clearance level and
decreased the accumulation of N (ε)-(carboxymethyl)
lysine and its receptors for advanced glycation end prod-
uct (AGE) expressions in kidney [19]. Radix Ginseng Alba
improved hyperglycemia in KKAy mice, possibly by
blocking intestinal glucose absorption and inhibiting
hepatic glucose-6-phosphatase, while Radix Ginseng Palva
Insulin signal pathway and insulin insensitive Figure 2
Insulin signal pathway and insulin insensitive. The inner part of IR reveals a tyrosine kinase activity and coupled with pro-
teins of Src-homology-collagen-like protein (SHC) and multifunctional docking proteins IRS-1 and IRS-2. The interaction of 
insulin and IR activates its tyrosine activity and phosphorylates the coupled SHC and subsequently activates, in turn, a series of 
signal proteins, including the growth factor receptor-binding protein 2 (Grb2), and the ras small guanosine 5'-triphosphate-
binding protein. The in turn signaling leads to an activation of the MAPK cascade involved in mitogenesis and the open status of 
a hexose transporter protein (GLUTs), which is located in the cell membrane and is the only pump to take into glucose for 
cells. The decreased serine/threonine phosphorylation of IR, inactivates hexokinase and glycogen synthase, as well as defects in 
the phosphorylation of glucose transporter protein (GLUT4) and genetic primary defect in mitochondrial fatty acid oxidation, 
leading to insulin resistance and an increase of triglyceride synthesis contribute to this insulin insensitivity. The action sites of 
hypoglycemia herbs are indicated with an arrow.Chinese Medicine 2009, 4:11 http://www.cmjournal.org/content/4/1/11
Page 4 of 11
(page number not for citation purposes)
has a similar effect through the up-regulation of adi-
pocytic PPAR-y protein expression and inhibition of intes-
tinal glucose absorption [20].
The treatment of the C57BL/Ks db/db mice with Panax gin-
seng  berry extract (150 mg/kg of body weight) signifi-
cantly lowered the fasting blood glucose levels on day 5
and achieved euglycemia on day 12 [21]. Berry extract
showed marked anti-obesity effect in obese ob/ob and db/
db mice [22]. Red ginseng lowered hemoglobin A1C to
normal range and improved insulin sensitivity [21]. Sim-
ilarly, extract of American ginseng berry also lowered fast-
ing blood glucose levels significantly in diabetic ob/ob
mice receiving daily berry juice at 0.6 ml/kg. This hypogly-
cemic effect continued for at least ten days after the treat-
ment. In addition, reduction of body weight was also
observed [23].
While both ginseng root and berry possess anti-diabetic
effects [24], ginseng berry seems to be more potent in anti-
hyperglycemic activity [25]. Furthermore, only ginseng
berry showed marked anti-obesity effects in ob/ob mice
[24,26].
A total of 705 components have been isolated from gin-
seng, such as ginsenosides, polysaccharides, peptides and
polyacetylenic alcohols, among which ginsenosides are
believed to be responsible for ginseng's efficacy [27].
Pharmacological sequential trials of three components,
i.e. (1) fat-soluble components, (2) ginseng saponins and
(3) a third component with hypoglycemic activity identi-
fied the most active components (100-fold more effective
than the original water-soluble extract of the ginseng
root). Ginseng's clinical efficacy is thought to be medi-
cated by multiple factors [27,28]: the component panax-
ans (panaxans A to E) elicits hypoglycemia in both
normal and diabetic mice; the component adenosine
inhibits catecholamine-induced lipolysis; both compo-
nents of carboxylic acid and peptide 1400 inhibit catecho-
lamine-induced lipolysis in rat epididymal fat pads; and
the component DPG-3-2 provokes insulin secretion in
diabetic and glucose-loaded normal mice [29]. EPG-3-2, a
Action sites of western medicine in diabetes treatment Figure 3
Action sites of western medicine in diabetes treatment. Hypoglycemic medicines restore euglycemia via several types, 
including insulin secretagogues (sulfonylureas, meglitinides), insulin sensitizers (biguanides, metformin, thiazolidinediones), 
alpha-glucosidase inhibitors (miglitol, acarbose).Chinese Medicine 2009, 4:11 http://www.cmjournal.org/content/4/1/11
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fraction related to DPG-3-2, also exhibits an anti-lipolytic
activity related to anti-obesity effects. Ginsenoside Rg3
inhibits adipocyte differentiation via PPAR-γ pathway in
rosiglitazone-treated cells and activates AMPK, a pathway
involved in the control of nutritional and hormonal mod-
ulation [30]. Ginsenoside Rh2 improves insulin sensitiv-
ity in rats fed with fructose rich chow [31]. Therefore, we
suggest that the whole extract of ginseng contains multi-
ple biologically active components that stimulate insulin
secretion, blocking intestinal glucose absorption and
enhancing glucose peripheral utilization.
Ginseng treatment for type II diabetes has been tested in
both animal models and human clinical trials. Panax
quinquefolius (10 g/1 kg diet) increases body weight and
decreases cholesterol levels, PPAR actions and triglyceride
metabolism in male Zucker diabetic fatty (ZDF) rats [32].
In human clinical trials, Panax quinquefolius improves
post-prandial glycemia in type II diabetic patients [33].
Single intravenous injection of ginsenoside Rh2 decreases
plasma glucose concentrations within 60 minutes in a
dose-dependent manner in rats fed with fructose rich
chow and STZ-induced insulin resistant rats [30]. A possi-
ble mechanism is that ginsenoside Rh2 promotes the
release of ACh from nerve terminals which stimulate mus-
carinic M (3) receptors in pancreatic cells to increase insu-
lin secretion [34].
Ginseng is also used to treat type I diabetic patients. Gin-
senosides at 0.1–1.0 g/mL inhibited cytokine-induced
apoptosis of β-cells. The action mechanism involves the
reduction of nitric oxide (NO), production of reactive
oxygen species (ROS) [35], inhibition on p53/p21 expres-
sion and inhibition on cleavage of caspases and poly
(ADP-ribose) polymerase (PARP) [36].
Not only does ginseng benefit serum glucose control in
diabetic patients, but also aids central nervous system
complications in them. Alternation expression of NOS
gene is implicated in the pathogenesis of numerous sec-
ondary complications in diabetic patients. In animal
models, enhanced NOS expression was detected in the
hippocampus of diabetic rats and the administration of
ginseng root suppressed NOS expression [33]. Pharmaco-
logical studies confirmed that ginseng possesses multiple
actions (central nervous system, neuroprotective, immu-
nomodulation and anticancer effects). Ginsenosides have
antioxidant, anti-inflammatory, anti-apoptotic and
immuno-stimulant properties [36].
Side-effects of ginseng include insomnia, diarrhea, vaginal
bleeding, breast pain, severe headache, schizophrenia and
fatal Stevens-Johnson syndrome [37]. The recommended
dosage of ginseng application is 1–3 g of root or 200–600
mg of extract [38]. Ginseng has the potential to prolong
bleeding time and therefore should not be used concom-
itantly with warfarin. Moreover, ginseng may cause head-
ache, tremulousness, and manic episodes in patients
treated with phenelzine sulfate [39]. Ginseng may inter-
fere with the actions of estrogens or corticosteroids and
may impede digoxin metabolism or digoxin monitoring
[40].
Momordica charantia (bitter melon)
Hypoglycemic effects of bitter melon were demonstrated
in cell culture, animal models [41] and human studies
[42]. The anti-diabetic components in bitter melon
include charantin, vicine, polypeptide-p, alkaloids and
other non-specific bioactive components such as anti-oxi-
dants. The major compounds in bitter melon methanol
extract, including 5-β, 19-epoxy-3-β, 25-dihydroxycucur-
bita-6,23(E)-diene (4) and 3-β,7-β,25-trihydroxycucur-
bita-5,23(E)-dien-19-al (5) showed hypoglycemic effects
in the diabetic male ddY mice at 400 mg/kg [43]. Olea-
nolic acid glycosides, compounds from bitter melon,
improved glucose tolerance in Type II diabetics by pre-
venting sugar from being absorbed into intestines.
Saponin fraction (SF) extracted from bitter melon with
PEG/salt aqueous two-phase systems showed hypoglyc-
emic activity in alloxan-induced hyperglycemic mice [44].
Bitter melon increased the mass of β cells in the pancreas
and insulin production [45,46]. With edible portion of
bitter melon at 10% level in the diet STZ-induced diabetic
rats, an amelioration of about 30% in fasting blood glu-
cose was observed [45].
Biochemical studies indicated that bitter melon regulated
cell signaling pathways in pancreatic β-cell, adipocytes
and muscles. Ethyl acetate (EA) extract of bitter melon
activates peroxisome proliferator receptors (PPARs) α and
γ [46,47], modulates the phosphorylation of IR and its
downstream signaling pathway, thereby lowering plasma
apoB-100 and apoB-48 in mice fed with high-fat diet
HFD. The momordicosides (Q, R, S and T) stimulate
GLUT4 translocation of the cell membrane and increase
the activity of AMP-activated protein kinase (AMPK) in
both L6 myotubes and 3T3-L1 adipocytes, thereby
enhancing fatty acid oxidation and glucose disposal dur-
ing glucose tolerance tests in both insulin-sensitive and
insulin-insensitive mice [48].
Bitter melon can be used as a dietary supplement herbal
medicine for the management of diabetes and/or meta-
bolic syndromes [49]. Reported adverse effects of bitter
melon include hypoglycemic coma, convulsions in chil-
dren, reduced fertility in mice, a favism-like syndrome,
increased enzyme activities of γ-glutamyl transferase and
alkaline phosphotase in animals and headaches inChinese Medicine 2009, 4:11 http://www.cmjournal.org/content/4/1/11
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humans. Bitter melon has an additive effect with other
glucose-lowering agents [50]. Bitter melon also reduces
adiposity in rats fed with HF diet [51].
Coptis chinensis (Huanglian)
Coptis chinensis is commonly used to treat diabetes in
China. Found in plant roots, rhizomes, stems and barks,
berberine is an isoquinoline alkaloids and the active
ingredient of Coptis chinensis.
Intragastric administration of berberine (100 and 200
mg/kg) in diabetic rats decreased fasting blood glucose
levels and serum content of TC, TG, LDL-c, increased
HDL-c and NO level, and blocked the increase of SOD
and GSH-px levels [52,53]. Multiple mechanisms may be
responsible for weight reduction and increased insulin
response induced by berberine. Glucose's uptake by adi-
pocytes is enhanced by berberine via GLUT1, adenosine
monophosphate-activated protein kinase and acetyl-
coenzyme A carboxylase phosphorylation [54]. Berberine
also increases the PPAR α/δ/γ protein expression in liver
[55], increases insulin receptor expression in liver and
skeletal muscle cells and improves cellular glucose con-
sumption in the presence of insulin [56]. Berberine
increases GLUT4 translocation in adipocytes and myo-
tubes [57], increases AMPK activity, decreases glucose-
stimulated insulin secretion (GSIS) and palmitate-poten-
tial insulin secretion in MIN6 cells and rat islets [58]. Fur-
thermore, berberine decreases significantly the enzyme
activity of intestinal disaccharidases and β-glucuronidase
in STZ-induced diabetic rats [59]. Recently, dihydrober-
berine (dhBBR), an identified BBR berberine derivative,
demonstrated in vivo beneficial effects in rodents fed with
high-fat [60].
Berberine may also relieve some diabetic complications.
Studies showed that berberine restored damaged pancreas
tissues in diabetic rats induced by alloxan [61]. Berberine
ameliorates renal dysfunction in rats with diabetic neph-
ropathy through controlling blood glucose, reduction of
oxidative stress and suppressing the polyol pathway [61].
Berberine ameliorates renal injury in STZ-induced diabe-
tes, not by suppression in both oxidative stress and aldose
reductase activities [61].
As berberine is an oral hypoglycemic agent in clinical
studies, the hypoglycemic effect of berberine was similar
to that of metformin in 36 adult patients of recently diag-
nosed type II diabetes [62]. Berberine also lowered fasting
blood glucose and postprandial blood glucose in 48 adult
patients of poorly controlled type II diabetes during a 3-
month period [62]. In the same trials, the fasting plasma
insulin, insulin insensitivity index, the total cholesterol
and low-density lipoprotein cholesterol reduced signifi-
cantly [62].
Chinese herbal preparations for diabetes
ADHF (anti-diabetes herbal formulation)
ADHF was studied in diet-induced type II diabetic ani-
mals (C57BL/6J mouse model). The blood glucose level
dropped markedly in the mice fed with a diet containing
4% or 8% ADHF. Other diabetic parameters such as insu-
lin insensitivity, histopathological changes in the pan-
creas and liver were also improved significantly in the
mice fed with ADHF [63].
Jiangtangkli
Jiangtangkli, a Chinese medicine formulation containing
Radix Ginseng (Renshen), improves insulin insensitivity by
modulating muscle fiber composition and TNF-α in skel-
etal muscles in hypertensive and insulin-insensitive fruc-
tose-fed rats [64].
YGD (Yerbe Mate-Guarana-Damiana)
YGD contains Yerbe Mate (leaves of Ilex paraguayenis),
Guarana (seeds of Paullinia cupana) and Damiana (leaves
of Turnera diffusa). The YGD capsule delayed the gastric
emptying significantly, and increased the time to feel gas-
tric fullness and reduced body weight significantly over 45
days on over-weighted patients treated in a primary health
care context.
BN (Byakko-ka-ninjin-to)
BN contains Radix Ginseng (Renshen), Rhizoma Anemar-
rhena (Zhimu), Radix Glycyrrhizae Uralensis (Gancao), gyp-
sum (Shigao) and rice. BN lowered blood glucose levels in
diabetic mice. Furthermore, ginseng-anemarrhena (or
ginseng-licorice) reduced the blood glucose levels more
than any individual component did. The study results
indicate that the anti-hyperglycemic effect of BN relies on
the cooperation of four crude therapeutic components
and Ca2+ [65].
The major goal in treating diabetes is to minimize eleva-
tion of blood glucose without causing abnormally low
levels of blood glucose. The action mechanisms for
hypoglycemic herbs are multiple (Figure 4), such as
increasing insulin secretion, enhancing glucose uptake by
adipose and muscle tissues, inhibiting glucose absorption
from intestine and inhibiting glucose production from
heptocytes.
Our literature search [66-99] reveals some commonly
used herbs for the management of diabetes mellitus
(Table 1).
Concerns over herbal treatment for diabetes
While the herbs discussed in this paper have shown effi-
cacy in lowering blood glucose in diabetes patients, the
line between whether an herb is a 'drug' or a dietary sup-
plement is unclear. The issues of standardization, charac-Chinese Medicine 2009, 4:11 http://www.cmjournal.org/content/4/1/11
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terization, preparation, efficacy and toxicity remain to be
addressed.
Herb-drug interaction and herb-herb interaction is
another concern. Contrary to some beliefs, herbs can have
side-effects. Unfortunately, herb-drug interactions in dia-
betic treatments have not been well documented. A
number of supplements are known to have intrinsic
effects on serum glucose, for example, ginseng is hypogly-
cemic in diabetic patients. Gliclazide is an oral hypoglyc-
emic (anti-diabetic) classified as a sulfonylurea. St John's
Wort increases the apparent clearance of gliclazide signif-
icantly. Diabetic patients receiving these at the same time
should be closely monitored for possible signs of reduced
efficacy [100].
Conclusion
Hypoglycemic herbs are used in Chinese medicine to treat
diabetes mellitus. Ginseng, bitter melon and Coptis chin-
ensis are used in both types I and II diabetes. The efficacy
of hypoglycemic herbs is achieved by increasing insulin
secretion, enhancing glucose uptake by adipose and mus-
cle tissues, inhibiting glucose absorption from intestine
and inhibiting glucose production from heptocytes.
Abbreviations
ADP: adenosine diphosphate; AGE: advanced glycation
end product; AMPK: AMP-activated protein kinase; ATP:
adenosine triphosphate; BUN: blood urea nitrogen; Cr:
Creatinine; DPP-4 (DDP IV): dipeptidyl peptidase IV;
GLP-1: glucagon-like peptide-1; Grb2: growth factor
receptor-binding protein 2; GLUTs: hexose transporter
protein; GLUT4: glucose transporter-4; HDL: high-density
lipoprotein; HFD: high-fat diet; IRS-1 and IRS-2: insulin
receptor substrate-1 and insulin receptor substrate-2; LDL-
C: lower-density lipoprotein cholesterol; MRSA: methicil-
lin resistant staphylococcus aureus; NO: nitric oxide;
PPAR: peroxisome proliferator receptors; ROS: reactive
oxygen species; PARP: poly (ADP-ribose) polymerase;
STZ: streptozotocin; SHC: src-homology-collagen-like
protein; SOD: superoxide dismutase; TC: total choles-
terol; TG: triglyceride; TNF-alpha: tumor necrosis factor
Action sites of herbs in diabetes treatment Figure 4
Action sites of herbs in diabetes treatment. The efficacy of hypoglycemia herbs has been mediated by increasing insulin 
secretion (ginseng, bitter melon, aloes, biophytum sensitivum), enhancing glucose uptake by adipose and muscle tissues (gin-
seng, bitter melon and cinnamon), inhibiting glucose absorption from intestine (myrcia and sanzhi) and inhibiting glucose pro-
duction from heptocytes (berberine, fenurgreek leaves).Chinese Medicine 2009, 4:11 http://www.cmjournal.org/content/4/1/11
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Table 1: Herbs commonly used in diabetes management
Herbs Components Anti-diabetic
Mechanism
Models of experiments 
or tests
Application and 
recommend 
dosage
Ref
Myrcia Flavanone glucosides 
(myrciacitrins) and 
acetophenone glucosides 
myrciaphenones)
Inhibit activity of aldose 
reductase and alpha-
glucosidase
Streptozotocin diabetic 
rats
Type II DM 66
Cinnamon Cinnulin PF(R) Improve insulin sensitivity, 
Decrease fasting blood glucose
Human Type II DM
Type I
67, 68, 69
Enicostemma 
littorale Blume
Increase the serum insulin 
through K(+)-ATP channel 
dependent pathway but did not 
require Ca2+ influx
Alloxan-induced diabetic 
rats
Type II DM 70
Biophytum 
sensitivum
Stimulating the synthesis/
release of insulin from the beta 
cells of Langerhans
Alloxan-induced diabetic 
rabbits
Type II DM 71
Ipomoea batatas Caiapo (ipomoea batatas) Decrease insulin insensitivity, 
increase adiponectin and 
decrease fibrinogen levels
Type II diabetic patients Type II (4 g/d) 
DM
72, 73
Tithonia 
diversifolia 
(Hemsl) A. Gray
Nitobegiku Reducing insulin insensitivity KK-Ay-mice Type II DM 74
Sangzhi Ramulus mori, SZ Alpha-glucosidase inhibitory 
effects
Alloxan induced diabetic 
rats
Type II DM 75
Galega officinalis Hypoglycemic effects is 
independent on a reduction of 
food intake
ob/ob animals Type II DM 76
Fenugreek leaves Similar to glibenclamide, 
hypoglycemic property and an 
anti-hyperlipidemic via 
inferenceiing carbohydrate 
metabolic enzymes
Streptozotocin induced 
diabetic rats, human
Type II DM 77, 78
Pterocarpus 
marsupium
Decrease HK (hexokinase), 
GK (glucokinase) and PFK 
(phosphofructokinase)
Human, alloxan-induced 
diabetic rats
Type II DM 79, 80
Vanadium Regulate activity of 
carbohydrate-metabolizing 
enzymes, and enhance 
expression of IRS-1 and 
GLUT4 mRNA in adipocytes
STZ-induced diabetic 
rats, dexamethasone-
induced insulin 
insensitivity in 3T3-L1 
adipocytes
Type II DM 81, 82
Artemisia 
scoparia
Scoparone (6,7-
dimethoxycoumarin
Anti-atherogenic effect; free 
radical scavenging properties; 
inhibited iNOS gene 
expression and inhibited NF-
kappaB activation.
Hyperlipidaemic diabetic 
rabbits, cytokine-induced 
beta-cell dysfunction
Type I DM, Type 
II DM
83, 84
Gymnema 
sylvestre
Gymnemic acids Controls the activities of 
phosphorylase, gluconeogenic 
enzymes and sorbitol 
dehydrogenase
Alloxan diabetic rabbits Type II DM 
complication
85, 86
Daio 
(Rhei Rhizoma)
Improve kidney function Patients Diabetic 
nephropathy
87
Lupinus termis Lupinus termis Regulates acetyl cholinesterase 
activity, AST (Aspartate 
aminotransferase), ALT 
(alanine aminotransferase) and 
LDH (lactate dehydrogenase)
Alloxan-induced 
diabetes, patients
Type II DM 88, 89
Tea EGCG Reduction of IL-1beta and IFN-
gamma-induced nitric oxide 
(NO) production and levels of 
NO synthase (iNOS
STZ-treated islets Type I DM, Type 
II DM
90, 91
Coccinia indica 
leaves
Coccinia indica leaf 
ethanoliextract (CLEt)
Antioxidant property of CLEt Streptozotocin-diabetic 
rats
Type II DM 92
Clausena anisata 
(Willd) Hook 
[family: Rutaceae]
Terpenoid and coumar Similar to glibenclamide Diabetic rats Type II DM 93Chinese Medicine 2009, 4:11 http://www.cmjournal.org/content/4/1/11
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alpha; UP24h: urine protein for 24 hours; ZDF: Zucker
diabetic fatty rats.
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